



Universiteit
Leiden
The Netherlands

Cardiac imaging characteristics of patients with COPD: prognostic implications

Goedemans, L.

Citation


Goedemans, L. (2023, April 11). *Cardiac imaging characteristics of patients with COPD: prognostic implications*. Retrieved from <https://hdl.handle.net/1887/3594029>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3594029>

Note: To cite this publication please use the final published version (if applicable).



Chapter 6

Influence of Chronic Obstructive Pulmonary Disease on Atrial Mechanics by Speckle Tracking Echocardiography in Patients with Atrial Fibrillation

Laurien Goedemans MD

Melissa Leung, MBBS, BSc(med), M. Biostat, PhD

Pieter van der Bijl, MB,ChB, MMed

Rachid Abou, MD

Ngoc Mai Vo, MD

Nina Ajmone Marsan, MD PhD

Victoria Delgado, MD PhD

Jeroen J Bax, MD PhD

Am J Cardiol 2021 Mar 15;143:60-66



The present study aimed to examine differences in left- and right atrial characteristics between atrial fibrillation (AF) patients with and without chronic obstructive pulmonary disease (COPD). For this, 420 patients (mean age 68 ± 10 years, 73% female) with first diagnosis of AF and baseline echocardiography were included. Of these, 143 COPD patients were compared with 277 patients without COPD matched by age, gender and body surface area. Additionally 38 healthy controls without cardiovascular risk factors, matched for age, were included. For all 3 groups, left atrial (LA) volumes and diameter, LA reservoir strain (LASr), left ventricular ejection fraction (LVEF), right atrial (RA) area and diameter, RA reservoir strain (RASr) and tricuspid annular plane systolic excursion (TAPSE) were evaluated on transthoracic echocardiography. Baseline characteristics were similar in patients with and without COPD except for smoking and a history of heart failure (42% vs. 11%, $p < 0.001$ and 48% vs 37%, $p = 0.036$ for COPD and non-COPD patients, respectively). Also, COPD patients less often used β -blockers (63% vs. 75%, $p = 0.017$). There were no significant differences in LVEF, LA volume and RA area between COPD and non-COPD patients. Compared to the controls, AF patients had impaired LVEF, LASr and RASr. Only RASr was significantly worse in COPD patients as compared to non-COPD patients (15.3% [9.0 – 25.1] vs. 19.6% [11.8 – 28.5], $p = 0.013$). Additionally, a trend towards worse RASr was observed with increasing COPD severity. In conclusion, AF patients with concomitant COPD have more impaired RA function compared to patients without COPD but with similar atrial size and LA function.

Keywords: Atrial fibrillation; chronic obstructive pulmonary disease; right atrial function

INTRODUCTION

Atrial remodelling is a key feature in the development and management of atrial fibrillation (AF). In particular atrial fibrosis and stiffness are related to treatment success and adverse events such as incident stroke.(1, 2) AF is a common comorbidity in patients with chronic obstructive pulmonary disease (COPD).(3) Previous research has been dedicated to characterization of the left atrium (LA). However, AF not only affects the LA but also the right atrium (RA). In patients with COPD, right-sided pressure overload is common due to secondary pulmonary hypertension which could lead to RA remodelling and dysfunction.(4) Additionally, studies have described a higher prevalence of RA foci in AF patients with chronic lung disease.(5, 6) Better understanding of the substrate of AF in COPD patients could lead to more targeted treatment strategies. The objective of this study was to evaluate differences in left- and right atrial size and function in AF patients with and without COPD by applying conventional and advanced echocardiography. Secondly, comparison with healthy controls will be performed to assess the degree of RA remodelling and functional impairment in AF.

6

Methods

Patients with AF who were referred to our tertiary care centre for electrical cardioversion between April 1995 and December 2015 were evaluated. For all patients, the first admission with AF was identified. AF was diagnosed based on the European Society of Cardiology guidelines for the management of AF.(7) COPD was defined preferably by pulmonary function testing in accordance with the most recent guidelines (post-bronchodilator fixed ratio of FEV1/FVC <0.70).(8) Otherwise, thorough chart review including referral letters and inhalation medication use was considered to identify patients with COPD. Subsequently, a control group of AF patients without COPD was selected from patients admitted for AF during the same time period matched by age, gender and body surface area (BSA) at a 1:2 case-control design. Patients with other pulmonary diseases (i.e. asthma, pulmonary hypertension not secondary to COPD, interstitial disease) were excluded prior to matching. Finally, an age-matched control group of healthy subjects without cardiovascular risk factors and without structural heart disease was selected from a database of patients referred for cardiac evaluation including transthoracic echocardiography (TTE). Referral reasons for these patients included evaluation of chest pain, dyspnoea, syncope, palpitations or preoperative assessment for non-cardiac surgery. Patients with prior surgical mitral- or tricuspid valve repair or replacement and absence of suitable echocardiographic images for atrial strain analysis were excluded. Figure 1 illustrates the selection of the final study population. For this retrospective analysis of clinically acquired data, the institutional review board waived the need for patient written informed consent.

Demographic and clinical data including cardiovascular risk factors, co-morbidities, laboratory values (haemoglobin and creatinine levels) and medication use were collected from the electronic patient records. Subsequently, the CHA₂DS₂-VASc score was calculated (congestive heart failure/left ventricular dysfunction [1 point], hypertension [1 point], age ≥ 75 years [2 points], diabetes mellitus [1 point], previous stroke or transient ischemic attack [2 points], history of vascular disease [1 point], age 65 – 74 years [1 point] and female sex [1 point]).(7)




Figure 1. Flowchart of patient selection. AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; MVR, mitral valve repair or replacement; TVP, tricuspid valve annuloplasty.

For echocardiographic analysis, the first TTE performed after diagnosis of AF was selected. TTE was performed with the patient in the left lateral decubitus position using a commercially available ultrasound system and transducer (Vivid 7 and E9, 3.5 MHz or M5S probe, GE Healthcare, Horten, Norway). All images retrieved during the time span of the study were digitally stored on hard disks for off-line analysis, including 2D speckle tracking echocardiography (STE) (EchoPAC, version BT13, GE Healthcare, Horten, Norway). Left ventricular ejection fraction (LVEF) was calculated using the Simpson's biplane method in accordance with current recommendations.(9) LV diastolic function was evaluated with E/e' ratio, derived from the pulsed wave tissue Doppler images (TDI) at the septal mitral annulus. LA maximal volume was assessed in the apical 4-chamber view by using Simpson's single plane method. Subsequently, LA volume was indexed to BSA. Maximal LA diameter was obtained from the parasternal long-axis view. Severity

of mitral- and tricuspid regurgitation was categorized (0= none, 1=mild, 2=moderate, 3=severe) based on current recommendations.(10) Color-coded tissue TDI was used to assess total atrial conduction time (PA-TDI) by measuring the time between the onset of the P-wave on the surface ECG and the peak of the A wave on the TDI velocity recording, as previously described.(2) For RA assessment, RA transverse diameter and RA area were measured on the right ventricular (RV) focused apical 4-chamber view in end-systole.(9) Tricuspid annular plane systolic excursion (TAPSE) was evaluated by applying M-mode in the apical 4-chamber view, as a measure of RV systolic function.(9) Systolic pulmonary artery pressure (SPAP) was estimated as the sum of the peak tricuspid regurgitation and RA pressure derived from the inferior vena cava diameter and inspiratory collapse, as recommended.(9)

Atrial strain was evaluated with 2D-STE in the apical 4-chamber view using appropriate frame rates. For RASr, the RV focused 4-chamber view was used.(11) Images with foreshortened LA or RA were excluded. The myocardial region of interest was manually traced and the width was adjusted to include the atrial wall and exclude the pericardium, left atrial appendage and pulmonary veins.(11) Subsequently, the software automatically tracks the myocardial cycle and segments with poor tracking quality are rejected, which can be overruled by the observer after visual assessment of tracking quality. LASr and RASr were measured as the peak longitudinal strain during ventricular systole by referencing the ECG to the onset of the QRS complex (Figure 2).

Statistical analysis was performed using the SPSS software (version 24, IBM SPSS statistics for windows, Armonk, New York). Categorical data are presented as frequencies and percentages. Continuous data are presented as mean \pm standard deviation (SD) or median [25th – 75th percentile] when non-normally distributed. For categorical variables, differences between COPD patients, non-COPD patients and healthy controls were compared with the χ^2 test. Comparison of continuous data between groups was performed using one-way analysis of variance (ANOVA) or a Kruskal-Wallis test, as appropriate. Post-hoc Bonferroni correction was applied to evaluate differences between COPD and non-COPD patients with adjustment for multiple testing. A two-tailed p-value of <0.05 was considered statistically significant.




Figure 2. Left- and right atrial strain analysis in atrial fibrillation (AF) patients. Example of left atrial reservoir strain (LASr; panel A) and right atrial reservoir strain (RASr; panel B) analysis in an AF patient with chronic obstructive pulmonary disease. Both RASr (10.5%) as well as LASr (10.0%) are markedly reduced.

Results

A total of 458 subjects (mean age 68 ± 10 years, 71% female) were included in the present study. The population consisted of 143 AF patients with COPD, 277 AF patients without COPD and 38 healthy controls without cardiovascular risk factors and structural heart disease (Figure 1). Of the COPD patients, 26 (18%) had mild COPD (GOLD class 1), 71 (50%) had moderate COPD (GOLD class 2) and 17 (12%) had severe COPD (GOLD class 3 and 4). (8) The GOLD classification could not be applied to 29 COPD patients (20%).

The baseline clinical characteristics of AF patients with and without COPD and control patients are shown in Table 1. AF patients were predominantly female whereas only half of the control patients were female ($p=0.004$). Compared to patients without COPD, COPD

patients were more likely to be smokers and more often had a history of coronary artery disease and heart failure. In terms of antiarrhythmic medication use, COPD patients less frequently used β -blockers and more often used digoxin when compared to patients without COPD. No differences in haemoglobin levels or kidney function were observed between patients with and without COPD although both groups had significantly higher creatinine levels compared to controls ($p=0.017$).

LASr assessment was feasible in 448 (98%) patients and RASr assessment in 436 (95%) patients. Furthermore, PA-TDI could only be measured in 234 (51%) patients because the remaining patients were in AF during echocardiography.

Table 1. Baseline characteristics for patients with and without chronic obstructive pulmonary disease and healthy controls.

Variable	COPD		Healthy controls (n=38)	p-value (all groups)	p-value* (COPD vs. no COPD)
	Yes (n=143)	No (n=277)			
Age (years \pm SD)	69 \pm 10	68 \pm 9	66 \pm 9	0.436	ns
Women	105 (73%)	201 (73%)	18 (47%)	0.004	ns
Body surface area, kg/m ² \pm SD	2.0 \pm 0.2	2.0 \pm 0.2	1.9 \pm 0.2	0.005	ns
Smoking	61 (43%)	31 (11%)	0 (0%)	<0.001	<0.001
Hypertension	108 (76%)	211 (76%)	0 (0%)	<0.001	ns
Diabetes mellitus	30 (21%)	44 (16%)	0 (0%)	0.007	ns
Thyroid disease	14 (10%)	27 (10%)	5 (13%)	0.801	ns
Hypercholesterolemia	78 (55%)	157 (57%)	0 (0%)	<0.001	ns
Obstructive sleep apnea	6 (4%)	9 (3%)	0 (0%)	0.434	ns
History of coronary artery disease	71 (50%)	109 (39%)	0 (0%)	<0.001	0.043
History of heart failure	69 (48%)	104 (38%)	0 (0%)	<0.001	0.035
Previous myocardial infarction	42 (29%)	68 (25%)	0 (0%)	0.001	ns
CHA ₂ DS ₂ -VASc \geq 2	125 (85%)	231 (83%)	-	-	ns
Hemoglobine, mmol/l	8.5 \pm 1.1	8.6 \pm 1.3	8.5 \pm 0.7	0.749	ns
Creatinine, μ mol/l	104 \pm 57	94 \pm 42	78 \pm 16	0.017	ns
Anticoagulant	108 (76%)	194 (70%)	0 (0%)	<0.001	ns
Angiotensin-converting enzyme inhibitor	93 (65%)	173 (63%)	0 (0%)	<0.001	ns
Diuretic	67 (47%)	116 (42%)	1 (3%)	<0.001	ns
Antiarrhythmic medication:					
β -blocker	91 (64)	208 (75)	0 (0%)	<0.001	0.014
Amiodarone	17 (12)	17 (6)	0 (0%)	0.020	0.042
Calcium antagonist [§]	21 (15)	28 (10)	0 (0%)	0.030	ns
Digoxin	26 (18)	25 (9)	0 (0%)	0.001	0.006
COPD therapy:					
Short acting β_2 -agonist [†]	22 (15%)	-	-	-	-
Long acting β_2 -agonist [†]	82 (57%)	-	-	-	-
Inhaled corticosteroid [†]	92 (64%)	-	-	-	-

*p-value derived from ANOVA or chi-square test with Bonferroni's multiple comparison in COPD patients vs. no COPD patients. Thyroid disease was defined as any recorded history of hypo- or hyperthyreodism or newly diagnosed by first admission with laboratory tests. Hypercholesterolemia was defined as previously diagnosed hypercholesterolemia, treatment with lipid-lowering agents, low-density lipoprotein \geq 3.0 mmol/L in low-to-moderate risk groups, \geq 2.6 mmol/L in high-risk groups and \geq 1.8 mmol/L in very high-risk groups. [§]Verapamil or diltiazem. [†] frequency and percentage of COPD patients. COPD, chronic obstructive pulmonary disease; SD, standard deviation. Continuous variables are presented as mean \pm SD.

Table 2 displays the echocardiographic characteristics of the 3 groups. Compared to the control patients, AF patients with and without COPD had larger LV volumes and worse LVEF ($61\pm 6\%$ vs. $50\pm 13\%$ vs. $50\pm 13\%$, $p<0.001$ for controls and AF patients with and without COPD, respectively). AF patients had larger atrial volumes and diameters. PA-TDI, a measure of total atrial conduction time, was significantly shorter in control patients as compared to AF patients with and without COPD (130 ± 36 vs. 139 ± 30 vs. 153 ± 44 ms, $p=0.003$ for controls, COPD patients and non-COPD patients, respectively). Interestingly, both LASr and RASr were significantly reduced in AF patients (Figure 3A and 3B).




Figure 3. Left- and right atrial strain analysis in control patients and atrial fibrillation (AF) patients with and without chronic obstructive pulmonary disease (COPD). Control patients (green) have a significantly higher left- (LA) and right (RA) atrial reservoir strain compared to AF patients with (red) and without (blue) COPD. AF patients with COPD have significantly reduced RA strain values compared to AF patients without COPD (Panel B) and similar LA strain (Panel A). Boxes represent median and interquartile range, whiskers demonstrate the minimal and maximal values. COPD, chronic obstructive pulmonary disease; LA, left atrial; RA, right atrial.

When comparing AF patients with and without COPD, no differences were observed for LVEF, E/e', LA volumes or atrial conduction time. Although LASr was lower in COPD patients, the difference was not statistically significant (14.2% [$9.7 - 22.3$] vs. 16.3% [$9.5 - 24.2$], $p=0.836$, Figure 3A). Rates of significant (moderate or severe) mitral- or tricuspid regurgitation were similar in both groups. Concerning the right sided measurements, RA diameter and area were similar in COPD and non-COPD patients. However, RA function was significantly worse in COPD patients demonstrated by a lower RASr (15.3% [$9.0 - 25.1$] vs. 19.6% [$11.8 - 28.5$], $p=0.013$; Figure 3B). Supplementary material Table S1 and Figure S1 show a tendency towards more reduced atrial strain with increasing COPD severity, which is most pronounced for RASr ($p=0.017$ for all groups).

Table 2. Echocardiographic characteristics of patients with and without chronic obstructive pulmonary disease and healthy controls.

Variable	COPD		Healthy controls (n=38)	p-value (all groups)	p-value* (COPD vs. no COPD)
	Yes (n=143)	No (n=277)			
Left-sided parameters:					
Left ventricular end-systolic volume (ml)	67 ± 57	63 ± 46	40 ± 13	0.009	1.000
Left ventricular end-diastolic volume (ml)	125 ± 72	119 ± 56	101 ± 23	0.094	1.000
Left ventricular ejection fraction (%)	50 ± 13	50 ± 13	62 ± 6	<0.001	1.000
E/e' ratio	17 ± 12	18 ± 10	11 ± 3	<0.001	0.950
Left atrial volume index (ml/m ²)	47 ± 20	46 ± 19	23 ± 6	<0.001	1.000
Left atrial diameter (mm)	46 ± 9	45 ± 8	36 ± 6	<0.001	0.531
Left atrial reservoir strain (%)	14.2 [9.7 – 22.3]	16.3 [9.5 – 24.2]	31.1 [26.2 – 38.9]	<0.001	0.836
PA-TDI (ms)	139 ± 30	153 ± 44	130 ± 36	0.003	0.076
Mitral regurgitation grade ≥ 2	19 (13%)	22 (8%)	0 (0%)	0.025	ns
Right-sided parameters:					
Right atrial area (cm ²)	21.6 ± 7	20.6 ± 6	16.2 ± 4	<0.001	0.398
Right atrial diameter (mm)	45 ± 8	44 ± 9	38 ± 8	<0.001	0.834
Right atrial reservoir strain (%)	15.3 [9.0 – 25.1]	19.6 [11.8 – 28.5]	42.8 [33.7 – 48.3]	<0.001	0.013
Tricuspid annular plane systolic excursion (mm)	17.4 ± 5.3	18.7 ± 5.5	21.7 ± 4.5	<0.001	0.056
Systolic pulmonary arterial pressure (mmHg)	39 ± 12	37 ± 12	24 ± 6	<0.001	0.076
Tricuspid regurgitation grade ≥ 2	6 (4%)	9 (3%)	0 (0%)	0.433	ns
Pacemaker lead right ventricle	25 (18%)	48 (17%)	0 (0%)	0.020	ns

*p-value derived from ANOVA or Kruskal-Wallis test with Bonferroni's multiple comparison in COPD patients vs. no COPD patients. Continuous variables are presented as mean±SD or median [25th-75th percentile]. COPD, chronic obstructive pulmonary disease

Discussion

It is widely recognized that COPD is a common comorbidity among patients with AF. Large AF registries have demonstrated the detrimental effect of COPD on all-cause- and cardiovascular mortality.(3) A substudy of the Euro Heart Survey also demonstrated that COPD was an independent predictor of unsuccessful ECV and AF recurrences within one year after cardioversion.(12)

There is a large body of literature describing LA remodelling in AF. LA enlargement is a known risk factor for AF in the general population and our results show a similar degree of LA dilatation in patients with and without COPD. Hence, differences in treatment success or prognosis between these patient populations might not be explained by LA characteristics only. In addition to size and volume, LA fibrosis is a major determinant of AF development and persistence or recurrence after treatment. 2DSTE strain analysis as well as prolonged PA-TDI, have emerged as surrogates of (atrial) fibrosis and have been correlated with treatment success and stroke risk.(1, 2) In concurrence with previous studies, we found an impaired LASr and a prolonged PA-TDI in AF patients with and

without COPD, confirming the early presence of structural atrial remodelling. Interestingly, PA-TDI was shorter in AF patients with COPD compared to AF patients without COPD. This could be explained by the different sensitivity of LASr and PA-TDI in reflecting structural changes of the LA myocardium. In addition, PA-TDI could only be assessed in half of the patients having sinus rhythm during echocardiography.

In addition to the LA, recent literature has suggested the importance of RA remodelling in AF. Data regarding RA function in AF is scarce: Govindan et al.(13) have performed 2DSTE in 30 AF patients undergoing ablation therapy, finding greater RA booster strain (>11.5%) to be independently associated with sinus rhythm maintenance up to 1 year. Our study only concerns reservoir strain since this is generally considered to best reflect atrial compliance and fibrosis. In addition, it has the advantage of being measurable when AF is present.(11) A few studies on RA remodelling and dysfunction in COPD patients have been performed: Bai et al(14) examined LA and RA strain in 87 AF patients with chronic lung disease (63 with COPD) divided according to AF recurrence after ablation therapy. Overall, the patients had reduced peak LA and RA strain of $19.11 \pm 10.75\%$ and $19.65 \pm 10.96\%$, respectively. Patients with AF recurrence had significantly lower LA and RA strain.(14) Importantly, both LA and RA strain separately were associated with AF recurrence after ablation and a combination of RA and LA strain showed the strongest association with the endpoint.(14) Our study focussed on differences between patients with and without COPD, yet considering the impact of combined LA and RA dysfunction might provide useful insights in the future.

Some studies have identified a higher prevalence of non-pulmonary vein (PV) foci in COPD patients compared to patients without COPD.(6, 15) Moreover, the majority of these non-PV foci originated from the RA. It is hypothesized that pulmonary hypertension in COPD patients leads to haemodynamic overload and stretching of the RA, contributing to the right-sided origin of AF. Gu et al.(6) support this theory by reporting a correlation between pulmonary arterial pressure and RA triggers. An electrophysiological study in 68 AF patients also demonstrated longer RA conduction time in COPD patients.(15) Similarly, RA electromechanical delay measured from the tricuspid annulus with TDI in 41 COPD patients without overt cardiac disease was significantly longer compared to controls.(16)

This observational study is subject to the inherent limitations of the retrospective design. In one fifth of the COPD patients, the severity of the disease could not be identified due to the absence of pulmonary function data. However, the echocardiographic characteristics of this group were very similar to COPD patients with moderate disease severity and may therefore be considered representative of the entire COPD group. The study might have been underpowered to detect differences between mild, moderate and severe COPD which are therefore presented in the supplementary material. Furthermore, for all patients the first occurrence of AF was identified but echocardiography at that timepoint was not available for all patients and the echocardiogram with the closest proximity was analysed. Few echocardiographic studies were performed within 3

weeks after cardioversion, resulting in a possible effect of atrial stunning on atrial strain analysis. Finally, atrial strain was analysed with 2DSTE software originally designed for left ventricular strain analysis, but has been validated for atrial strain assessment in multiple studies and is discussed in a recent consensus document for standardization of LA and RA deformation imaging.⁽¹¹⁾

To the best of our knowledge, the present study is the first to identify a significantly larger reduction of RASr in AF patients with COPD when compared with their counterparts. Importantly, a relation appears to exist between COPD severity and RA dysfunction, warranting early screening when COPD is diagnosed and close monitoring during follow-up. Future studies examining RASr as a surrogate of a right sided AF substrate are essential to confirm the usefulness in clinical practice.

Conflicts of interest

The Department of Cardiology of the Leiden University Medical Centre received unrestricted research grants from Abbott Vascular, Bayer, Bioventrix, Biotronik, Medtronic, Boston Scientific Corporation, GE Healthcare and Edwards Lifesciences. V.D. received speaker fees from Abbott Vascular, Edwards Lifesciences, GE Healthcare and Medtronic. N.A.M. and J.J.B. received speaker fees from Abbott Vascular.

References

1. Longobardo L, Todaro MC, Zito C, Piccione MC, Di Bella G, Oreto L, Khandheria BK, Carerj S. Role of imaging in assessment of atrial fibrosis in patients with atrial fibrillation: state-of-the-art review. *Eur Heart J Cardiovasc Imaging* 2014;15(1):1-5.
2. Leung M, van Rosendael PJ, Abou R, Ajmone Marsan N, Leung DY, Delgado V, Bax JJ. Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry. *Eur Heart J* 2018;39(16):1416-1425.
3. Durham MT, Cyr DD, Lopes RD, Thomas LE, Tsuang WM, Gersh BJ, Held C, Wallentin L, Granger CB, Palmer SM, Al-Khatib SM. Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. *Int J Cardiol* 2016;202:589-594.
4. Rottlaender D, Motloch LJ, Schmidt D, Reda S, Larbig R, Wolny M, Dumitrescu D, Rosenkranz S, Erdmann E, Hoppe UC. Clinical Impact of Atrial Fibrillation in Patients with Pulmonary Hypertension. *PLOS ONE* 2012;7(3):e33902.
5. Roh S-Y, Choi J-I, Lee JY, Kwak J-J, Park J-S, Kim J-B, Lim H-E, Kim Y-H. Catheter Ablation of Atrial Fibrillation in Patients With Chronic Lung Disease. *Circ Arrhythm Electrophysiol* 2011;4(6):815-822.
6. Gu JUN, Liu XU, Tan H, Zhou LI, Jiang W, Wang Y, Liu Y, Gu J. Impact of Chronic Obstructive Pulmonary Disease on Procedural Outcomes and Quality of Life in Patients with Atrial Fibrillation Undergoing Catheter Ablation. *J Cardiovasc Electrophysiol* 2013;24(2):148-154.
7. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Group ESD. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;37(38):2893-2962.
8. Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. *N Eng J Med* 2019;381(13):1257-1266.
9. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015;28(1):1-39 e14.
10. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S, Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. *J Am Soc Echocardiogr* 2017;30(4):303-371.
11. Badano LP, Kolias TJ, Muraru D, Abraham TP, Aurigemma G, Edvardsen T, D'Hooge J, Donal E, Fraser AG, Marwick T, Mertens L, Popescu BA, Sengupta PP, Lancellotti P, Thomas JD, Voigt JU, Industry r, Reviewers: This document was reviewed by members of the ESDC. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle


- tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *Eur Heart J Cardiovasc Imaging* 2018;19(6):591-600.
12. Pisters R, Nieuwlaet R, Prins MH, Le Heuzey J-Y, Maggioni AP, Camm AJ, Crijns HJGM, for the Euro Heart Survey I. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. *EP Europace* 2012;14(5):666-674.
 13. Govindan M, Kiotsekoglou A, Saha SK, Camm AJ. Right atrial myocardial deformation by two-dimensional speckle tracking echocardiography predicts recurrence in paroxysmal atrial fibrillation. *J Echocardiogr* 2017;15(4):166-175.
 14. Bai Y, Zhao Y, Li J, Zhang Y, Bai R, Du X, Dong JZ, He YH, Ma CS. Association of peak atrial longitudinal strain with atrial fibrillation recurrence in patients with chronic lung diseases following radiofrequency ablation. *Intern Med J* 2018;48(7):851-859.
 15. Hayashi T, Fukamizu S, Hojo R, Komiyama K, Tanabe Y, Tejima T, Nishizaki M, Hiraoka M, Ako J, Momomura S, Sakurada H. Prevalence and electrophysiological characteristics of typical atrial flutter in patients with atrial fibrillation and chronic obstructive pulmonary disease. *Europace* 2013;15(12):1777-1783.
 16. Caglar IM, Dasli T, Turhan Caglar FN, Teber MK, Ugurlucan M, Ozmen G. Evaluation of atrial conduction features with tissue doppler imaging in patients with chronic obstructive pulmonary disease. *Clin Res Cardiol* 2012;101(8):599-606.

Supplementary material

Table S1. Echocardiographic characteristics of atrial fibrillation patients without COPD and with different stages of COPD. COPD severity was defined as mild (GOLD class 1), moderate (GOLD class 2) or severe (GOLD class 3 and 4).

	No COPD (n=277)	Mild COPD (n=26)	Moderate COPD (n=71)	Severe COPD (n=17)	Unknown COPD severity (n=30)	p-value (all groups)
Left-sided parameters:						
Left ventricular end-systolic volume (ml)	63 ± 46	64 ± 39	70 ± 60	79 ± 86	58 ± 39	0.586
Left ventricular end-diastolic volume (ml)	119 ± 56	123 ± 50	128 ± 72	136 ± 115	111 ± 56	0.547
Left ventricular ejection fraction (%)	50 ± 13	51 ± 15	49 ± 13	46 ± 11	51 ± 13	0.773
Left atrial volume index (ml/m ²)	46 ± 19	47 ± 24	49 ± 20	38 ± 17	48 ± 19	0.341
Left atrial diameter (mm)	45 ± 8	45 ± 10	47 ± 8	45 ± 10	47 ± 9	0.496
Left atrial reservoir strain (%)	16.3 [9.5 – 24.2]	18.9 [12.2 – 30.1]	14.1 [8.8 – 25.4]	14.4 [8.4 – 20.1]	12.7 [8.9 – 17.8]	0.122
PA-TDI (ms)	153 ± 44	143 ± 29	137 ± 28	135 ± 43	146 ± 33	0.259
Mitral regurgitation grade ≥ 2, n (%)	22 (8)	6 (23)	9 (13)	1 (6)	3 (10)	0.123
Right-sided parameters:						
Right atrial area (cm ²)	20.6 ± 6	20 ± 8	22 ± 6	21 ± 7	23 ± 6	0.325
Right atrial diameter (mm)	44 ± 9	44 ± 8	44 ± 8	45 ± 8	45 ± 10	0.848
Right atrial reservoir strain (%)	19.6 [11.8 – 28.5]	19.3 [10.9 – 26.4]	15.9 [7.9 – 27.0]	13.8 [9.8 – 25.1]	14.7 [5.4 – 22.1]	0.017
Tricuspid annular plane systolic excursion (mm)	18.7 ± 5.5	19.2 ± 6.1	16.9 ± 4.9	17.8 ± 5.3	16.6 ± 5.3	0.051
Systolic pulmonary artery pressure (mmHg)	37 ± 12	40 ± 11	41 ± 12		37 ± 12	0.078
Tricuspid regurgitation grade ≥ 2, n (%)	9 (3)	2 (8)	2 (3)	0 (0)	2 (7)	0.543
Pacemaker lead right ventricle, n (%)	48 (17)	3 (12)	11 (16)	5 (29)	6 (21)	0.604

Continuous variables are presented as mean±SD or median [25th–75th percentile]. COPD, chronic obstructive pulmonary disease.



6

Figure S1. Left- and right atrial strain analysis in atrial fibrillation patients with different stages of chronic obstructive pulmonary disease (COPD). COPD severity was defined as mild (GOLD class 1), moderate (GOLD class 2) or severe (GOLD class 3 and 4). Bar graphs represent median values and 75th percentile. COPD, chronic obstructive pulmonary disease; LA, left atrial; RA, right atrial.